Latest News and Press Releases

How chronic disease prevalence, infectious disease testing, AI investment, personalized medicine and regulatory change are shaping the diagnostics industry

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...

Grand Cayman, Cayman Islands, May 14, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell...

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or...

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its...

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...

CAMBRIDGE, United Kingdom and NEW YORK, May 12, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response...

Anaveon announces presentation of positive ANV600 Clinical Data at ASCO 2026 and actively seeks partners for its legacy Oncology Portfolio.